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Abstract
 
Toll-like receptors (TLRs) are innate recognition molecules for microbial products, but their
direct interactions with corresponding ligands remain unclarified. LPS, a membrane constituent
of gram-negative bacteria, is the best-studied TLR ligand and is recognized by TLR4 and MD-2,
a molecule associated with the extracellular domain of TLR4. Although TLR4-MD-2 recognizes
LPS, little is known about the physical interaction between LPS and TLR4-MD-2. Here, we
demonstrate cell surface LPS–TLR4-MD-2 complexes. CD14 greatly enhances the formation
of LPS–TLR4-MD-2 complexes, but is not coprecipitated with LPS–TLR4-MD-2 complexes,
suggesting a role for CD14 in LPS loading onto TLR4-MD-2 but not in the interaction itself
between LPS and TLR4-MD-2. A tentative dissociation constant (K
 
d
 
) for LPS–TLR4-MD-2
complexes was 
 
 
 
3 nM, which is 
 
 
 
10–20 times lower than the reported K
 
d
 
 for LPS–MD-2 or
LPS–CD14. The presence of detergent disrupts LPS interaction with CD14 but not with
TLR4-MD-2. E5531, a lipid A antagonist developed for therapeutic intervention of endotoxin
shock, blocks LPS interaction with TLR4-MD-2 at a concentration 100 times lower than that
required for blocking LPS interaction with CD14. These results reveal direct LPS interaction
with cell surface TLR4-MD-2 that is distinct from that with MD-2 or CD14.
Key words: innate immunity • cell surface molecule • activation • macrophage
 
Introduction
 
The innate immune response is the first line of defense
against microbial pathogens, and plays an important role in
activating acquired immunity. Recently, the toll-like receptor
(TLR) family has been discovered as specific pathogen recog-
nition molecules in the innate immune system (1). Although
TLRs specifically recognize microbial products (2), detection
of direct interaction between TLRs and their ligands has
been unsuccessful thus far.
LPS is a principal component of gram-negative bacteria
that activates the innate immune system, and is one of the
best-studied microbial products (3). Great progress has
been made recently in the identification of LPS recognition
molecules. Core components are CD14 (4), MD-2 (5), and
toll-like receptor (TLR) 4 (6, 7). CD14 binds to LPS and
augments LPS responses. TLR4-MD-2 is thought to work
downstream of this initial binding. TLR4 is a type I mem-
brane protein consisting of extracellular leucine-rich repeats
and an intracellular signaling domain. MD-2 is associated
with the extracellular leucine-rich repeats of TLR4. Both
TLR4 and MD-2 are indispensable for LPS responses because
mice lacking either TLR4 or MD-2 do not respond to LPS
(8, 9). Despite these evidences for LPS recognition by
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Abbreviations used in this paper:
 
 PGN, peptidoglycan; TLR, toll-like receptor.T
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TLR4-MD-2, little is known for LPS interaction with
TLR4-MD-2.
Although soluble MD-2 was shown to bind to LPS (10),
LPS–MD-2 needs to eventually form LPS–TLR4-MD-2
complexes on the cell surface to trigger a signal. However,
little is known about LPS–TLR4-MD-2 complexes. Re-
cent works suggested CD14-dependent LPS interaction
with TLR4-MD-2 by using chemical cross-linking be-
tween LPS and TLR4-MD-2 (11–13). However, these pa-
pers showed merely the physical proximity between LPS
and TLR4-MD-2, and do not necessarily demonstrate di-
rect LPS interaction with TLR4-MD-2 in physiological
condition. Direct interaction between LPS and TLR4-
MD-2 still needs to be demonstrated and characterized in
responding cells.
Here, we show, with a newly established monoclonal
antibody to TLR4-MD-2, LPS–TLR4-MD-2 complexes
on the cell surface, and we demonstrate direct LPS interac-
tion with TLR4-MD-2 that is distinct from that with MD-2
or CD14.
 
Materials and Methods
 
Reagents. 
 
LPS from 
 
Escherichia coli
 
 055:B5 and lipid A purified
from 
 
Salmonella minnesota
 
 were purchased from Sigma-Aldrich.
Synthetic lipid A and 
 
3
 
H-labeled lipid A were described previously
(14). E5531 was obtained from Eisai Research Institute. Sources of
other microbial products were described previously (8). mAbs to
LPS and lipid A were purchased from Hycult Biotechnology. De-
tergents such as Brij98 and 
 
N
 
-octyl-
 
 
 
-
 
d
 
-glucoside were purchased
from Sigma-Aldrich and Wako, respectively. Rabbit anti–mouse
TLR4 serum was established by immunized rabbits with TLR4
peptide (CSFNRIETSKGILQHFP), which is conjugated with
keyhole limpet hemocyanin.
 
Expression Constructs and Stable Transfectants. 
 
IL-3–dependent
Ba/F3 cells (15) were cultured in 10% FCS and RPMI 1640 sup-
plemented with 100 
 
 
 
M 2-mercaptoethanol and IL-3. The mouse
cDNAs encoding TLR4, MD-2, and CD14 were cloned into the
retrovirus vector pMX-puromycin (16). MD-2 was tagged with
the flag epitope at the COOH terminus. Ba/F3 cells expressing
TLR4 and MD-2flag with or without CD14 were established by
retroviral transduction. Ba/F3 cells expressing CD14 alone were
established by electroporation of expression vector pcDNA3 (In-
vitrogen) encoding mouse CD14. We have described previously
Ba/F3 cells expressing either MD-2 or TLR4, both of which were
tagged with the flag epitope at the COOH terminus (indicated as
MD-2f and TLR4f, respectively; reference 17). These cells were
further transfected with pcDNA3 encoding CD14 (indicated as
CD14/MD-2f and CD14/TLR4f, respectively).
 
Establishment of mAbs to Mouse TLR4-MD-2 and CD14. 
 
A
rat was immunized on the foot pads with normal rat kidney cells
expressing CD14 and TLR4-MD-2 that had been stimulated
with 1 
 
 
 
g/ml lipid A. 1 wk later, cells from draining lymph
nodes were fused with SP2/0 myeloma cells. Sa15-21 and Sa2-8
mAb (rat IgG2a/
 
 
 
) were selected for further analyses because
they specifically reacted with Ba/F3 cells expressing TLR4-MD-2
or CD14, respectively. The mAbs were purified from ascites ob-
tained from SCID mice.
 
Cell Staining and Flow Cytometry. 
 
Single cell suspensions
were incubated at 2 
 
 
 
 10
 
5
 
 cells/100 
 
 
 
l on ice for 15 min with
the primary antibodies diluted in staining buffer (PBS containing
 
2.5% FCS and 0.01% NaN
 
3
 
). Cells were washed in staining
buffer, and incubated with R-PE–conjugated goat anti–rat IgG
Ab (Southern Biotechnology Associates Inc.), FITC-conjugated
goat anti–mouse IgG (BD Biosciences), or R-PE–conjugated
streptavidin (BD Biosciences) for 15 min. The mAbs used were as
follows: rat anti–mouse TLR4-MD-2 (MTS510 and Sa15-21);
rat anti–mouse CD14, 4C1 (18); or anti-LPS (Hycult Biotech-
nology). Flow cytometry analysis was performed using a FACS-
Calibur™ system (Becton Dickinson).
 
Cell Surface Biotinylation, Immunoprecipitation, and Immunoprob-
ing. 
 
Cell surface proteins were biotinylated with 6-((6-((bio-
tinoyl)amino)hexanoyl)amino) hexanoic acid, succinimidyl ester
(biotin-XX; Molecular Probes) dissolved in saline containing 10
mM Hepes, pH 7.5, for 30 min at room temperature. Cells were
washed and lysed in lysis buffer consisting of 50 mM Tris-HCl,
pH 7.4, 150 mM NaCl, 1% Triton X-100, 50 mM iodoaceta-
mide, 1 mM PMSF, 10 
 
 
 
g/ml aprotinin, leupeptin, and 5 mM
EDTA. After 30 min of incubation on ice, nuclei were removed
by centrifugation. mAb-coupled beads were added to cell lysate
and rotated for 2 h at 4
 
 
 
C. Beads were washed in 5
 
  
 
diluted lysis
buffer, and bound proteins were subjected to SDS-PAGE and
Western blotting with streptavidin–alkaline phosphatase conjugate
(Calbiochem). The primary reagents for immunoprobing were as
follows: Sa2-8 for CD14; anti-LPS (Hycult Biotechnology) for
LPS; anti–IkB-
 
 
 
 (BD Biosciences); and anti-actin (Sigma-Aldrich).
The second reagents were alkaline phosphatase–conjugated as fol-
lows: goat anti–rabbit IgG (Bio-Rad Laboratories); goat anti–rat
IgG; and goat anti–mouse IgG (American Qualex).
 
3
 
H-Lipid A Binding Assay. 
 
3
 
H-lipid A was synthesized as de-
scribed previously (14). The specific radioactivity was 
 
 
 
10,000
cpm/ng. Ba/F3 stable transfectants (10
 
8
 
 cells/sample) were stimu-
lated with various concentrations of 
 
3
 
H-lipid A for 30 min at
37
 
 
 
C. After washing, cells were subjected to immunoprecipitation
as described in the preceding paragraph. Precipitated radioactivity
was counted by a liquid scintillation counter (Aloka). To exclude
nonspecific binding to TLR4-MD-2 in Fig. 6 (a and b), cpm asso-
ciated with MTS510 was subtracted from that with Sa15-21.
 
Results
 
No Detectable LPS Binding to Cells Expressing TLR4-MD-2
but Not CD14.
 
To investigate direct interaction be-
tween LPS and cell surface TLR4-MD-2, we used flow
cytometry staining with an anti-LPS mAb. Ba/F3 stable
transfectants separately expressing TLR4 alone, CD14
alone, TLR4-MD-2, or CD14 and TLR4-MD-2 were es-
tablished, and cell surface expression of TLR4-MD-2 and
CD14 was tested for in each cell line (Fig. 1, left and mid-
dle columns). These lines were stimulated with LPS, and
cell surface LPS was detected with the anti-LPS mAb. Cell
surface LPS was detected only on cells expressing CD14
(right column). LPS binding was largely abolished when
anti-CD14 mAb was included during LPS stimulation (un-
published data). In sharp contrast, we could not detect any
cell surface LPS on cells expressing TLR4-MD-2 (Fig. 1),
revealing a clear difference from soluble MD-2 that
showed CD14-independent binding to LPS with an affin-
ity similar to that for CD14 (10).
 
Anti–TLR4-MD-2 mAb MTS510 Staining Is Down-regu-
lated upon Lipid A Stimulation.
 
Next, we studied a LPS-
dependent change in TLR4-MD-2. We showed previouslyT
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that cell surface expression of TLR4-MD-2 on peritoneal
macrophages decreases upon LPS stimulation, as detected by
a mAb to TLR4-MD-2, MTS510 (19). We were able to
see a similar phenomenon in Ba/F3 transfectants and mac-
rophage line RAW264. The decrease in MTS510 staining is
observed with lipid A or LPS stimulation but not with other
stimuli, such as peptidoglycan (PGN) or CpG oligodeoxy-
nucleotide (Fig. 2 and not depicted). The down-regulation
became apparent with as little as 20 ng/ml in RAW264 and
200 ng/ml in the transfectant, and as early as 10 min after
LPS stimulation (unpublished data). Interestingly, lipid
A–induced decrease in MTS510 staining was not clear in
the absence of membrane CD14 (Fig. 2, left column). In
keeping with this, anti-CD14 mAb was able to inhibit LPS-
triggered decrease in MTS510 staining (unpublished data).
 
Newly Established mAb to TLR4-MD-2 Reveals the LPS-
induced Change of TLR4-MD-2.
 
We asked the cause of
the lipid A–dependent decrease in MTS510 staining. We
considered three possibilities. First, TLR4-MD-2 may be
internalized upon LPS stimulation as described previously
(20). Second, MD-2 may be dissociated from TLR4;
MTS510 does not bind to TLR4 alone (17). Finally,
TLR4-MD-2 remains on the cell surface but LPS stimula-
tion may alter TLR4-MD-2 to a conformation, which
MTS510 cannot bind. Biochemical analyses revealed that
MTS510 reacted with TLR4-MD-2 before LPS stimulation
but not after LPS stimulation. For further study, we estab-
lished a novel mAb to TLR4-MD-2, Sa15-21, which was
 
able to react with LPS-stimulated TLR4-MD-2, to which
MTS510 did not bind. Sa15-21 was similar to MTS510 in
that it specifically immunoprecipitated TLR4-MD-2 but
not TLR4 alone (Fig. 3 a). However, Sa15-21 recognized
an epitope distinct from the MTS510 epitope, because these
two mAbs did not crossblock with each other (unpublished
data). Sa15-21 remained reactive with LPS- and lipid
A–stimulated cells expressing CD14 and TLR4-MD-2 as
revealed by flow cytometry staining (Fig. 3 b). Similar results
were obtained with RAW264 cells (unpublished data). Bio-
chemical analyses were conducted with Sa15-21 mAb (Fig.
3 c). Ba/F3 cells expressing TLR4-MD-2 and CD14 or
RAW264 cells were subjected to LPS stimulation, cell sur-
face biotinylation, and immunoprecipitation with Sa15-21
or MTS510. MTS510 precipitated cell surface TLR4-MD-2
from cells treated with medium alone or a lipid A antago-
nist, E5531, but not from cells stimulated with LPS. In
sharp contrast, Sa15-21 was able to precipitate cell surface
TLR4-MD-2 from LPS-stimulated cells. Together, LPS-
stimulated TLR4-MD-2 remains on the cell surface, but is
likely to undergo the LPS-dependent conformation change,
which is not recognized by MTS510 mAb.
 
LPS and TLR4-MD-2 Forms Stable Complexes on the Cell
Surface.
 
Next, we hypothesized that the change of TLR4-
MD-2 may accompany the direct interaction between LPS
and TLR4-MD-2. To address this possibility, we con-
ducted immunoprecipitation of lipid A–stimulated TLR4-
MD-2 with Sa15-21, and coprecipitation of lipid A was
Figure 1. No detectable LPS binding to cells expressing TLR4-MD-2
without CD14. Ba/F3 stable transfectants were stained with anti–TLR4-
MD-2 mAb (MTS510, left) or anti-CD14 mAb (4C1, middle), followed
by goat anti–rat IgG-PE. (right) Ba/F3 transfectants were stimulated with
1  g/ml LPS at 37 C for 30 min, washed, and stained with anti-LPS
mAb, followed by goat anti–mouse IgG-FITC. All the open histograms
depict staining with the second reagent alone.
Figure 2. LPS down-regulates MTS510 binding to cell surface TLR4-
MD-2. Ba/F3 cells expressing TLR4-MD-2 (left) or CD14 TLR4-MD-2
(middle), or a macrophage line RAW264 (right) were stimulated with
medium alone, 1  g/ml lipid A, 10  g/ml peptidoglycan (PGN), or 100
 M CpG DNA as indicated. After washing, cells were stained with biotin-
ylated MTS510 followed by streptavidin-PE.T
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probed with anti–lipid A antibody (Fig. 4 a, bottom). We
were able to detect lipid A coprecipitation with TLR4-
MD-2 by Sa15-21 mAb but not by MTS510 mAb. Inter-
estingly, MTS510 was able to precipitate TLR4-MD-2
from lipid A–stimulated cells as detected by anti-TLR4
polyclonal mAb (Fig. 4 a, top). The amount of precipitated
TLR4 seems to be smaller than that from cells without
stimulation. Precipitated TLR4-MD-2 is likely to be lo-
cated inside the cells, because we could not detect the pre-
cipitation by MTS510 of LPS-stimulated, cell surface
TLR4-MD-2 (Fig. 3 c). Lipid A was not present in these
MTS510 precipitates containing intracellular TLR4-MD-2
(Fig. 4 a, bottom). We also examined CD14 coprecipita-
tion with lipid A–TLR4-MD-2 complexes to address the
possibility that association of lipid A with TLR4-MD-2 is
mediated by CD14. We could not detect CD14 in lipid
A–TLR4-MD-2 complexes precipitated by Sa15-21,
demonstrating the direct interaction between lipid A and
TLR4-MD-2 (Fig. 4 a, middle).
Similar results were obtained with LPS and anti-LPS anti-
body (unpublished data). We also detected LPS–TLR4-
MD-2 complexes with native cells such as a macrophage
line RAW264 (unpublished data). Thus, the LPS- or lipid
A–dependent change of TLR4-MD-2 accompanies the for-
mation of LPS–TLR4-MD-2 complexes on the cell surface.
 
A Role for Membrane CD14 in LPS Interaction with TLR4-
MD-2.
 
Membrane CD14 was required for the LPS-
dependent conformation change of TLR4-MD-2 (Fig. 2),
but CD14 was not present in lipid A–TLR4-MD-2 com-
plexes (Fig. 4 a). Next, we addressed a role for membrane
CD14 in LPS interaction with TLR4-MD-2 by using Ba/
F3 transfectants separately expressing MD-2flag, TLR4flag,
CD14, TLR4-MD-2flag, CD14 and TLR4flag, CD14 and
MD-2flag, and CD14 and TLR4-MD2flag (Materials and
Methods). We used 
 
3
 
H-lipid A to stimulate the transfec-
tants. Immunoprecipitation was conducted with MTS510,
Sa15-21, anti-flag mAb, or anti-CD14 mAb. Precipitated
radioactivity is shown (Fig. 4 b and not depicted). Appre-
ciable counts were detected in the precipitate with Sa15-21
from Ba/F3 transfectant expressing CD14 and TLR4-MD-2,
but not clearly from that expressing TLR4-MD-2. Lipid
A coprecipitation was also observed with anti-flag mAb
only from the transfectant expressing CD14 and TLR4-
MD-2flag (Fig. 4 b). We could not detect lipid A coprecip-
itation with the anti-flag mAb from cells separately express-
ing MD-2flag, TLR4flag, TLR4-MD-2flag, CD14 and
TLR4flag, or CD14 and MD-2flag (Fig. 4 b and not de-
picted). We had similar results with LPS, coprecipitation of
which was detected by anti-LPS mAb (unpublished data).
These results demonstrate an important role for membrane
CD14 in facilitating the establishment of the interaction
between lipid A and TLR4-MD-2. However, CD14 is not
required for the interaction itself, because membrane
 
Figure 3.
 
A novel mAb to TLR4-MD-2 reveals the LPS-triggered
change of cell surface TLR4-MD-2. (a) Immunoprecipitation with anti-
flag (top) or Sa15-21 (bottom) was conducted with Ba/F3 transfectants
expressing the indicated molecules (Materials and Methods). The precipitates
were probed with rabbit anti–mouse TLR4 sera followed by goat anti–
rabbit alkaline phosphatase. Only immature, smaller TLR4 is detected in
cells expressing TLR4 alone (top, TLR4f and CD14/TLR4f), because
TLR4 without MD-2 cannot reach the cell surface. (b) Ba/F3 transfectants
expressing CD14 and TLR4-MD-2 were stimulated with medium alone,
1 
 
 
 
g/ml lipid A, or 1 
 
 
 
g/ml LPS at 37
 
 
 
C for 30 min. Cells were stained
with biotinylated MTS510 mAb or Sa15-21 as indicated, followed by
streptavidin-PE. Open histograms depict staining with streptavidin-PE
alone. (c) Ba/F3 cells expressing TLR4-MD-2 and CD14 (top) or
RAW264 (bottom) were stimulated with medium, 2 
 
 
 
g/ml LPS, or 2
 
 
 
g/ml lipid A antagonist E5531 as indicated at 37
 
 
 
C for 30 min. After
washing, cells were subjected to cell surface biotinylation, detergent lysis,
immunoprecipitation with MTS510 mAb (right three lanes) or Sa15-21
mAb (left three lanes), SDS-PAGE (7.5% polyacrylamide under non-
reducing conditions), and electroblotting. Precipitated cell surface TLR4
was probed with streptavidin–alkaline phosphatase conjugate.T
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CD14 is not present in lipid A–TLR4-MD-2 complexes
(Fig. 4 a). It should be noted that only 1–2% of cell bound
lipid A was coprecipitated with TLR4-MD-2 (Fig. 4 b).
 
LPS Interaction with TLR4-MD-2 Is More Stable than That
with CD14.
 
Unexpectedly, lipid A coprecipitation was
not detected in the CD14 precipitates with anti-CD14
mAb (Fig. 4, a [right lane]). We prepared cell lysates for
immunoprecipitation using lysis buffer containing 1% Tri-
ton X-100, which might disrupt LPS interaction with
CD14. To address this possibility, soluble CD14–LPS
complexes were immunoprecipitated with anti-CD14 in
the absence of detergents (Fig. 5). LPS was clearly copre-
cipitated with soluble CD14. Moreover, LPS coprecipita-
tion was abolished by the presence of detergents such as
1% Triton X-100, 0.5% 
 
N
 
-octyl-
 
 
 
-
 
d
 
-glucoside, and 1%
Brij98, indicating that these detergents disrupted LPS inter-
action with CD14. In view of the possibility that interac-
tion between LPS and TLR4-MD-2 can only be observed
in the presence of detergent, we conducted immunopre-
cipitation of sonicated cell membrane in the absence of de-
tergent. The results using mechanically solubilized cell ly-
sate clearly demonstrated physical association between LPS
and TLR4-MD-2 (unpublished data). Thus, LPS interac-
tion with TLR4-MD-2 seems to be distinct from and more
stable than with CD14.
We could not detect lipid A–MD-2 complexes by im-
munoprecipitation of MD-2 from cells expressing MD-
2flag or CD14
 
 
 
 MD-2flag (Fig. 4 b and not depicted). It is
possible that lipid A–MD-2 interaction might be disrupted
in the presence of detergents as lipid A–CD14 interaction.
 
Binding Properties of Lipid A Interaction with TLR4-MD-2.
 
It was difficult to directly compare lipid A–TLR4-MD-2
with lipid A–MD-2 or with lipid A–CD14, because lipid
A was not coprecipitated with CD14 or MD-2 (Fig. 4,
a and b). Immunoprecipitation in our binding assay seems
to be too rigorous for lipid A–CD14 or lipid A–MD-2
complexes. Despite such a rigorous binding assay, the bind-
ing of lipid A and TLR4-MD-2 was dose-dependent and
reached saturation (Fig. 6 a). Therefore, we tentatively
figured out an apparent dissociation constant (K
 
d
 
) for lipid
A–TLR4-MD-2 complexes (Fig. 6 b). We were able to
obtain the tentative K
 
d
 
 of 
 
 
 
3 nM for lipid A–TLR4-MD-2,
which was, even in a rigorous condition, 
 
 
 
10–20 times
Figure 4. Lipid A–TLR4-MD-2 complexes. (a) Ba/F3 cells expressing
TLR4-MD-2 and CD14 (108/10 ml sample) were incubated with 5  g/ml
lipid A at 37 C for 30 min. Cells were subjected to washing, detergent
lysis, immunoprecipitation (with mAbs to TLR4-MD-2, MTS510, and
Sa15-21, or an mAb to CD14, Sa2-8, and SDS-PAGE [17.5% for lipid A,
10% for CD14, and 7.5% for TLR4; under nonreducing conditions]), and
electroblotting. Precipitates were probed with anti-TLR4 polyclonal Ab,
anti-CD14 mAb (Sa2-8), or anti–lipid A mAb, followed by alkaline phos-
phatase–conjugated secondary antibodies. Nonspecific signals detecting
IgG heavy chains were observed in the precipitates probed with anti-
CD14 mAb (left four lanes). (b) A variety of Ba/F3 stable transfectants
(2.5   107/sample) were stimulated with 3H-lipid A (0.75  Ci/sample)
at 37 C for 30 min. Cells were subjected to washing, detergent lysis, and
immunoprecipitation with MTS510, Sa15-21, anti-flag, or anti-CD14
mAbs. Precipitated radioactivity was counted by scintillation counter.
Similar results were obtained from three independent experiments using
3H-lipid A.
Figure 5. LPS–CD14 complexes
are disrupted by detergents. Super-
natant from Ba/F3 cells expressing 1
ml CD14 (cultured up to 4–5  
106/ml) was incubated with 3  g/ml
LPS at 37 C for 30 min; sCD14 in
the supernatant from Ba/F3 cells
expressing CD14 was immunopre-
cipitated with anti-CD14 mAb
(4C1). The indicated detergents (1%
Triton X-100, 0.5% N-octyl- -d-
glucoside, and 1% Brij98) were in-
cluded before immunoprecipitation.
Precipitated LPS or CD14 was
probed with anti-LPS mAb and
anti-CD14 mAb (Sa2-8), followed
by alkaline phosphatase–conjugated
secondary antibodies.T
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lower than the reported dissociation constant for LPS–MD-2
or LPS–CD14 complexes (65 and 30–74 nM, respectively;
references 10, 21).
 
Lipid A Antagonist E5531 Acts on TLR4-MD-2.
 
To
further characterize interaction between LPS and TLR4-
MD-2, we used E5531, a potent LPS antagonist developed
for therapeutic intervention of endotoxin shock (22). E5531
was shown to block LPS binding to macrophage cells, sup-
posedly by antagonizing LPS binding to membrane CD14
(23). However, further analysis demonstrates that E5531 in-
hibits CD14-independent, TLR4-MD-2 agonists (24). We
hypothesized that E5531 acts on TLR4-MD-2 rather than
on CD14. Ba/F3 cells expressing CD14 and TLR4-MD-2
were pretreated with graded concentrations of E5531 for 30
min and stimulated with LPS at 3 
 
 
 
g/ml. We added E5531
up to 30 
 
 
 
g/ml, 10 times higher than the concentration of
LPS. E5531 was able to block CD14-dependent LPS bind-
ing to cells at concentrations higher than 10 
 
 
 
g/ml (Fig. 7
a, right). For further confirmation of the antagonistic effect
of E5531, we also conducted LPS coprecipitation with solu-
ble CD14. The supernatant from Ba/F3 cells expressing
CD14 was exposed to 3 
 
 
 
g/ml LPS with or without the in-
dicated concentration of E5531. Soluble CD14 was precipi-
tated with anti-CD14 mAb and LPS coprecipitation was
probed with anti-LPS. LPS coprecipitation gradually de-
creased with increasing concentrations of E5531, leading to
complete inhibition at 10 
 
 
 
g/ml of E5531 (Fig. 7 b).
Next, we examined the effect of E5531 on TLR4-MD-2.
E5531 completely antagonized LPS-dependent down-
regulation of MTS510 staining at a concentration as low as
0.1 
 
 
 
g/ml (Fig. 7 a, middle). LPS association with TLR4-
MD-2 was disrupted with concentrations of E5531 higher
than 0.1 
 
 
 
g/ml (Fig. 7 c). Furthermore, E5531 was able to
inhibit LPS-stimulated IkB
 
 
 
 degradation at 0.1 
 
 
 
g/ml
(Fig. 7 d). With regard to sensitivity to E5531 treatment,
LPS signaling correlated precisely with LPS interaction
with TLR4-MD-2 but not with CD14.
 
Discussion
 
A newly established mAb to TLR4-MD-2, Sa15-21,
demonstrated lipid A–TLR4-MD-2 complexes on the cell
surface by precipitating lipid A–TLR4-MD-2 complexes
from cells expressing TLR4-MD-2 and CD14 (Fig. 4). Lipid
A interaction with TLR4-MD-2 was dose-dependent and
saturable (Fig. 6 a). Cell surface TLR4-MD-2 interacts with
lipid A at a tentative K
 
d
 
 of 
 
 
 
3 nM, which is  10–20 times
lower than that of soluble MD-2 (65 nM) or CD14 (74 nM;
reference 10). This binding assay uses immunoprecipitation
and is different from a conventional ligand binding assay. We
could not directly compare, with the binding assay, TLR4-
MD-2 with CD14 or MD-2 with regard to lipid A interac-
tion because lipid A was not coprecipitated with CD14 or
MD-2, probably due to the presence of detergents (Figs. 4
and 5). However, even in such a rigorous condition where
affinity decreased, our binding assay still yielded the Kd for
lipid A–TLR4-MD-2 that is still lower than the reported Kd
for lipid A–CD14 or lipid A–MD-2. In keeping with the
lower Kd, LPS–TLR4-MD-2 complexes were disrupted by
lipid A antagonist E5531 at  100 times lower concentration
than LPS–CD14 complexes (Fig. 7). Together, the present
results demonstrated LPS–TLR4-MD-2 complexes that in-
teract with each other at higher affinity and are more stable
than LPS–MD-2 or LPS–CD14 complexes. The higher af-
finity for TLR4-MD-2 than that of soluble MD-2 may be
due to associated TLR4 that might directly bind to lipid A
or strengthen interaction between MD-2 and lipid A.
Although LPS interaction with soluble MD-2 does not
require CD14 (10), membrane CD14 was required for LPS
interaction with TLR4-MD-2 (Fig. 4 b). Recent papers
suggest that LPS triggers CD14 association with TLR4-
MD-2 (11, 13). However, we could not detect CD14 asso-
ciation with LPS–TLR4-MD-2 complexes (Fig. 4 a). Even
if CD14 associates itself with LPS–TLR4-MD-2 complexes,
the association probably plays a minimal role in sustaining
the direct interaction between LPS and TLR4-MD-2; LPS
interaction with TLR4-MD-2 is higher in affinity and more
stable than that with CD14. CD14 seems to have a role in
loading LPS onto TLR4-MD-2, which by itself showed lit-
tle binding to LPS (Fig. 1). It should be noted that CD14 is
not essential for LPS response. CD14 KO mice still show
significant LPS responses (25, 26). A CD14-independent
mechanism for loading LPS onto TLR4-MD-2 must be
present and is likely to be accelerated by membrane CD14.
We believe that a small number of LPS–TLR4-MD-2 com-
plexes are present on cells expressing TLR4-MD-2 without
CD14. The number of complexes is probably too small to
be detected in the present detection system. Interestingly,
only 1–2% of cell-associated lipid A was coprecipitated with
TLR4-MD-2, even with membrane CD14 (Fig. 4 b). The
CD14-independent lipid A loading mechanism might re-
strict the amount of lipid A to be loaded onto TLR4-MD-2.
Further study has to focus on molecular mechanisms under-
lying LPS loading onto TLR4-MD-2.
The unique mAb to TLR4-MD-2, MTS510, binds to
cell surface TLR4-MD-2 before LPS stimulation, but not af-
Figure 6. Binding properties of
lipid A interaction with TLR4-MD-2.
Ba/F3 stable transfectant expressing
CD14 and TLR4-MD-2 (108 cells/
10 ml medium) were stimulated
with various concentrations of 3H-
lipid A (0.003, 0.01, 0.03, 0.1, 0.3,
1, 3, and 10  Ci) for 30 min at
37 C. After washing, cells were sub-
jected to immunoprecipitation with
Sa15-21 or with MTS510. Precipi-
tated radioactivity was counted by a
liquid scintillation counter (Aloka).
Specific binding was obtained by
subtracting bound cpm with
MTS510 from that with Sa15-21.
Bound lipid A (cpm) was plotted
against input lipid A (cpm) in panel
a. Scatchard plot is shown in panel b.
Two independent experiments were
conducted and similar results were
obtained.T
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ter stimulation, demonstrating the ligand-dependent change
of TLR4-MD-2 (Figs. 2 and 3). The LPS-triggered change
of TLR4-MD-2 correlates perfectly with LPS–TLR4-MD-2
complex formation. It is possible that the LPS-dependent
change of TLR4-MD-2 reflects the conformation change of
TLR4-MD-2, which leads to dimerization of TLR4-MD-2
and delivering a signal. The LPS-dependent change of
TLR4-MD-2 may reveal a link between LPS interaction
and LPS signaling. Further studies on the antagonistic action
of E5531 may be important to address this issue, because
E5531 does not induce the LPS-dependent change and pre-
vents LPS interaction with TLR4-MD-2 (Fig. 7 a).
It has been described previously that E5531 inhibits LPS
binding to cells, suggesting competition with LPS in binding
to CD14 as an antagonistic mechanism (23). Because CD14
binds other microbial products in addition to LPS (27),
E5531 should be able to compete CD14 interaction with
these microbial products. However, E5531 is antagonistic to
LPS but not to other microbial products (e.g., PGN; refer-
ence 23). Moreover, E5531 inhibits CD14-independent
TLR4-MD-2 ligands (24). These results suggest that E5531
directly acts on TLR4-MD-2. The present experimental
system enabled us to address this question. E5531 inhibited
LPS interaction with TLR4-MD-2 at a concentration 100
times lower than that required for inhibiting LPS interaction
with CD14 (Fig. 7). Given that E5531 acts on TLR4-MD-2,
it is reasonable that E5531 antagonizes TLR4-MD-2 ligand
other than LPS. Thus, the present paper has revealed a novel
mechanism for the action of this lipid A antagonist.
The reported incidence of sepsis syndromes is increasing
dramatically in hospitalized patients. Despite aggressive
management, many patients die of endotoxin shock. E5531
was developed with an aim to neutralize endotoxin in vivo
(22). Here, we showed that E5531 targets TLR4-MD-2,
which mediates the adverse effects of endotoxin (8, 9).
TLR4-MD-2 is arguably a target for therapeutic interven-
Figure 7. E5531 acts on LPS
interaction with TLR4-MD-2 at
a concentration that does not af-
fect LPS binding to mCD14. (a)
Ba/F3 cells expressing TLR4-
MD-2 and CD14 were pre-
treated with or without E5531
(indicated concentration) at
37 C for 30 min. Cells were
stimulated with medium alone
or 3  g/ml LPS at 37 C for
30 min. After washing, cells
were stained with biotinylated
MTS510 mAb followed by
streptavidin-PE (left and middle
columns), or with anti-LPS fol-
lowed by goat anti–mouse IgG-
FITC (right column). Open histo-
grams  depict staining with the
secondary reagent alone. (b) 3
 g/ml LPS with indicated con-
centrations of E5531 was added
to the supernatant from Ba/F3
cells expressing CD14. sCD14 in
the supernatant was precipitated
with anti-CD14 mAb, followed
by immunoprobing with anti-LPS
(top) or anti-CD14 (bottom). (c)
After treatment with E5531 and
LPS as in panel a, cells were sub-
jected to cell surface biotinylation,
washing, detergent lysis, immunoprecipitation with Sa15-21, SDS-PAGE (polyacrylamide gel:
18.0% for LPS and 7.5% for TLR4; under nonreducing conditions), and electroblotting. Pre-
cipitated LPS (top) and cell surface TLR4 (bottom) were probed with anti-LPS mAb or alkaline
phosphatase–conjugated streptavidin, respectively. (d) After treatment with LPS and E5531 as
in panel c, cells were subjected to detergent lysis, SDS-PAGE, electroblotting, and immuno-
probing IkB  (top) or actin (bottom).T
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tion of endotoxin shock. The present work provides a the-
oretical background and assay system for further improve-
ment of lipid A antagonists and for development of other
therapeutic interventions for endotoxin shock.
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